{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:19:48Z","timestamp":1792466388661,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":813,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014547","name":"Parker Institute for Cancer Immunotherapy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014547","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015394","name":"American Society for Transplantation and Cellular Therapy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015394","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005410","name":"American-Italian Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004176","name":"Miltenyi Biotec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jtct.2020.10.022","type":"journal-article","created":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T14:04:06Z","timestamp":1609423446000},"page":"233-240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy"],"prefix":"10.1016","volume":"27","author":[{"given":"Marta","family":"Garcia-Recio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kitsada","family":"Wudhikarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Pennisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalia","family":"Alonso-Trillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni","family":"Shouval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishat O.","family":"Afuye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari Lynne","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie W.","family":"Batlevi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parastoo","family":"Dahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio A.","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Halton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josel","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Maloy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Mead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Lia","family":"Palomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Santomasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig S.","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Scordo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunjan L.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2020.10.022_bib0001","series-title":"WHO Classification of Tumours, revised 4th ed, volume 2","article-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017"},{"key":"10.1016\/j.jtct.2020.10.022_bib0002","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.25460","article-title":"Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment","volume":"94","author":"Liu","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2020.10.022_bib0003","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019 Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2020.10.022_bib0004","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2020.10.022_bib0005","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2020.10.022_bib0006","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude SL","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2020.10.022_bib0007","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2020.10.022_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T-cells","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2020.10.022_bib0009","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.tmrv.2019.01.005","article-title":"Risks and benefits of chimeric antigen receptor T-cell (CAR-T) therapy in cancer: a systematic review and meta-analysis","volume":"33","author":"Grigor","year":"2019","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.jtct.2020.10.022_bib0010","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T\u2011cell therapy\u2014assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtct.2020.10.022_bib0011","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtct.2020.10.022_bib0012","first-page":"375","article-title":"The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma","volume":"16","author":"Lulla","year":"2018","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.jtct.2020.10.022_bib0013","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/bloodadvances.2019000952","article-title":"Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management","volume":"4","author":"Pennisi","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2020.10.022_bib0014","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","article-title":"Diffuse large B-cell lymphoma","volume":"50","author":"Li","year":"2018","journal-title":"Pathology"},{"key":"10.1016\/j.jtct.2020.10.022_bib0015","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2020.10.022_bib0016","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2002-12-3837","article-title":"Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma","volume":"102","author":"Hamlin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2020.10.022_bib0017","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/bmt.2009.371","article-title":"Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT","volume":"45","author":"Perales","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2020.10.022_bib0018","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.bbmt.2015.07.032","article-title":"Indications for autologous and allogeneic hematopoietic cell transplantation\u00a0: guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Majhail","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2020.10.022_bib0019","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chron Dis"},{"key":"10.1016\/j.jtct.2020.10.022_bib0020","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2020.10.022_bib0021","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/sj.bmt.1701624","article-title":"The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma","volume":"23","author":"Moskowitz","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2020.10.022_bib0022","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2020.10.022_bib0023","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The Revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2020.10.022_bib0024","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1200\/JCO.2009.26.2493","article-title":"Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era","volume":"28","author":"Ziepert","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2020.10.022_bib0025","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.bbmt.2006.12.452","article-title":"The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission","volume":"13","author":"Lerner","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2020.10.022_bib0026","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bbmt.2016.10.017","article-title":"Hematopoietic cell transplantation comorbidity index (HCT- CI) predicts outcomes in patients with acute myeloid leukemia and myelodysplastic syndromes receiving CD34+ selected grafts for allogeneic hematopoietic cell transplantation","volume":"23","author":"Barba","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2020.10.022_bib0027","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.bbmt.2017.06.005","article-title":"Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in nonmyeloablative allogeneic stem cell transplantation","volume":"23","author":"Veeraputhiran","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2020.10.022_bib0028","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.bbmt.2017.06.014","article-title":"Hematopoietic cell transplantation-specific comorbidity index predicts morbidity and mortality in autologous stem cell transplantation","volume":"23","author":"Berro","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2020.10.022_bib0029","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.bbmt.2017.01.084","article-title":"Prognostic value of the Hematopoietic Cell Transplantation Comorbidity Index for patients undergoing reduced-intensity conditioning cord blood transplantation","volume":"23","author":"Salit","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl_1","key":"10.1016\/j.jtct.2020.10.022_bib0030","first-page":"4103","article-title":"Correlative analyses of patient and clinical characteristics associated with efficacy in tisagenlecleucel-treated relapsed\/refractory diffuse large B-cell lymphoma patients in the","volume":"134","author":"Westin","year":"2019","journal-title":"Juliet trial. Blood"},{"key":"10.1016\/j.jtct.2020.10.022_bib0031","article-title":"Comparison of CAR-T19 and autologous stem-cell transplantation for refractory\/relapsed non-Hodgkin's lymphoma","volume":"5","author":"Li","year":"2019","journal-title":"JCI insight"},{"key":"10.1016\/j.jtct.2020.10.022_bib0032","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2020.10.022_bib0033","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2020.10.022_bib0034","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2020.10.022_bib0035","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1007\/s11684-020-0751-3","article-title":"Different sites of extranodal involvement may affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimeric antigen receptor T cell therapy","volume":"14","author":"Zhou","year":"2020","journal-title":"Front Med"},{"key":"10.1016\/j.jtct.2020.10.022_bib0036","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2020.10.022_bib0037","doi-asserted-by":"crossref","first-page":"S232","DOI":"10.1016\/j.bbmt.2019.12.474","article-title":"A comparison of 2-year outcomes in ZUMA-1 (axicabtagene ciloleucel [Axi-Cel]) and SCHOLAR-1 in patients (Pts) with refractory large B cell lymphoma (LBCL)","volume":"26","author":"Neelapu","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl_1","key":"10.1016\/j.jtct.2020.10.022_bib0038","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1182\/blood-2019-129777","article-title":"Risk factors and characteristics of CRS in CAR-T treatment","volume":"134","author":"Zhiling","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2020.10.022_bib0039","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s12185-013-1490-x","article-title":"Chimeric antigen receptor modified T cell therapy for B cell malignancies","volume":"99","author":"Turtle","year":"2014","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2020.10.022_bib0040","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s40265-017-0690-8","article-title":"Chimeric antigen receptor (CAR) T cells: lessons learned from targeting of CD19 in B-cell malignancies","volume":"77","author":"Hay","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.jtct.2020.10.022_bib0041","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtct.2020.10.022_bib0042","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/bjh.15644","article-title":"Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy","volume":"183","author":"Hay","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2020.10.022_bib0043","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","article-title":"Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies","volume":"146","author":"Freyer","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jtct.2020.10.022_bib0044","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2020.10.022_bib0045","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood \u2013 brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"issue":"suppl_1","key":"10.1016\/j.jtct.2020.10.022_bib0046","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1182\/blood-2019-127305","article-title":"The lymphoma tumor microenvironment influences toxicity after CD19 CAR T cell therapy","volume":"134","author":"Jain","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2020.10.022_bib0047","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/neuonc\/noaa183","article-title":"Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes [e-pub ahead of print]","volume":"23","author":"Holtzman","year":"2021","journal-title":"Neuro Oncol"},{"issue":"suppl_1","key":"10.1016\/j.jtct.2020.10.022_bib0048","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1182\/blood-2019-127372","article-title":"Real-world analysis of adverse events associated with CAR T-cell therapy among adults age \u226565 years","author":"Zettler","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2020.10.022_bib0049","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaneurol.2020.2703","article-title":"Clinical predictors of neurotoxicity after chimeric antigen receptor T-cell therapy","volume":"77","author":"Rubin","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jtct.2020.10.022_bib0050","first-page":"46","article-title":"Comorbidities predict inferior survival in patients receiving chimeric antigen receptor T-cell therapy for relapsed\/refractory diffuse large B cell lymphoma: a multicenter analysis [e-pub ahead of print]","volume":"27","author":"Kittai","year":"2021","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636720300336?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636720300336?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T02:59:56Z","timestamp":1763002796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636720300336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S2666636720300336"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2020.10.022","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2020.10.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}